The authorization of Moderna's Spikevax BA.4/5 bivalent COVID-19 vaccine for use as a booster dose in children and adolescents aged 6-17 years by Health Canada is a positive development for the company. This approval expands the market for Moderna's vaccine, potentially increasing demand and revenues. As a result, the stock price is likely to go up in the short term.